Stomach flu vaccine shows promise in massive Kids' trial
NCT ID NCT05916326
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large phase 3 trial tested a new norovirus vaccine in 8,000 healthy children aged 6 months to 13 years. The vaccine targets two common norovirus strains (GⅠ.1 and GⅡ.4) that cause severe vomiting and diarrhea. Researchers compared vaccinated kids to those who got a placebo to see if the shot prevents moderate to severe stomach flu.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Norovirus bivalent vaccine (GⅠ.1/GⅡ.4)
- What this could lead to
- If successful, this vaccine could protect children against the most common causes of severe vomiting and diarrhea from norovirus.
- What could go wrong
- This is a completed trial, but results are not yet published. The vaccine may not work against all norovirus strains, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
8,000 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 13 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged from 6 months to 13 years old, and can provide legal identity certificate; * Volunteers and/or their guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent, and can participate in all planned follow-up visits ( by an authorized entrusted person on the premise of written authorization by the guardian the informed consent can be signed); * Those \<12 months old: born in full-term pregnancy (gestational week 37-42 weeks) and birth weight ≥ 2.5kg. Exclusion Criteria: First dose exclusion criteria: * Axillary body temperature \> 37.0°C ; * Have a history of chronic gastrointestinal diseases; * Had gastroenteritis requiring treatment or current diarrhea, vomiting or other digestive system diseases within 7 days; * Have a history of allergy to any excipients of the experimental vaccine (L-histidine, sodium chloride, aluminum hydroxide and water for injection, etc.); * Have a history of severe allergy to any vaccine or drug, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, Arthus reaction; * Have been diagnosed with congenital or acquired immunodeficiency, or received immunosuppressant treatment, such as the application of systemic glucocorticoid therapy for more than 2 consecutive weeks 2 months before vaccination, such as prednisone or similar drugs \> 5mg/day (note: use of topical and inhaled/nebulized steroids can participate); * Infectious diseases, such as: tuberculosis, viral hepatitis or parents infected with human immunodeficiency virus HIV; * Thrombocytopenia, any coagulation disorders, or intramuscular injection contraindications receiving anticoagulant therapy etc.; * The volunteer himself or his biological parents have a history of convulsions (except for febrile convulsions in children), epilepsy and mental illness; * Serious diseases or congenital malformations that may interfere with the conduct or completion of the research (including but not limited to: asthma and other respiratory diseases or during the attack of chronic bronchitis, Down syndrome, thalassemia, heart disease, encephalopathy, kidney disease, self immune diseases, genetic allergies, Guillain-Barre Syndrome, severe skin diseases, severe malnutrition, severe developmental disorders, etc.); * Asplenia, functional asplenia, and asplenia or splenectomy caused by any reason; * Have received blood or blood-related products or immune globulin within 3 months (hepatitis B immune globulin and rabies patient immune globulin are acceptable); * vaccinated inactivated/recombinant vaccines (non-live vaccines) within 7 days, and inoculate live attenuated vaccines or COVID-19 vaccines within 14 days; * Acute illness or acute exacerbation of chronic disease within 3 days; * Have taken antipyretic, analgesic or antiallergic drugs within 3 days; * Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit; * Participating in or planning to participate in another interventional research during the study process; * The investigators believe that the volunteers have other conditions that may interfere with the evaluation of the research purpose; * \<12 months old: the baby is born with abnormal labor process (dystocia, instrumental midwifery) or has a history of suffocation, nervous system damage, current pathological jaundice, perianal abscess, severe eczema; * If there have been serious adverse reactions after vaccination in the past, the investigator will determine whether the volunteer is enrolled or not according to the actual situation. If items 1, 3, 13, 14, and 15 of the exclusion criteria are met, the volunteer's enrollment will be postponed.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Norovirus infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jingxing County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
-
Laishui County Center for Disease Control and Prevention
Baoding, Hebei, China
-
Zhao County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Norovirus vaccine candidate put to the test in first human trial
- Can a pill stop the stomach bug? new oral norovirus vaccine put to the test
- 10,000 people tested: Cambodia's massive disease hunt begins
- Could a pill protect babies from stomach bugs? new vaccine trial in moms
- Could a pill stop the stomach bug? new vaccine trial shows promise